» Articles » PMID: 25248380

Intratumor Heterogeneity in Hepatocellular Carcinoma

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2014 Sep 25
PMID 25248380
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Morphologic intratumor heterogeneity is well known to exist in hepatocellular carcinoma (HCC), but very few systematic analyses of this phenomenon have been performed. The aim of this study was to comprehensively characterize morphologic intratumor heterogeneity in HCC. Also, taken into account were well-known immunohistochemical markers and molecular changes in liver cells that are considered in proposed classifications of liver cell neoplasms or discussed as molecular therapeutic targets.

Experimental Design: In HCC of 23 patients without medical pretreatment, a total of 120 tumor areas were defined. Analyzed were cell and tissue morphology, expression of the liver cell markers cytokeratin (CK)7, CD44, α-fetoprotein (AFP), epithelial cell adhesion molecule (EpCAM), and glutamine synthetase (GS) along with mutations of TP53 and CTNNB1, assayed by both Sanger and next-generation sequencing.

Results: Overall, intratumor heterogeneity was detectable in the majority of HCC cases (20 of 23, 87%). Heterogeneity solely on the level of morphology was found in 6 of 23 cases (26%), morphologic heterogeneity combined with immunohistochemical heterogeneity in 9 of 23 cases (39%), and heterogeneity with respect to morphologic, immunohistochemical, and mutational status of TP53 and CTNNB1 in 5 of 23 cases (22%).

Conclusions: Our findings demonstrate that intratumor heterogeneity represents a challenge for the establishment of a robust HCC classification and may contribute to treatment failure and drug resistance in many cases of HCC.

Citing Articles

HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity.

Andrade R, Perez-Rojas J, da Silva S, Miskinyte M, Quaresma M, Frazao L Cancers (Basel). 2025; 17(3).

PMID: 39941867 PMC: 11816190. DOI: 10.3390/cancers17030500.


Evolutionary View of Liver Pathology.

Dezso K, Paku S, Juhasz M, Kobori L, Nagy P Evol Appl. 2024; 17(12):e70059.

PMID: 39717436 PMC: 11664044. DOI: 10.1111/eva.70059.


Comprehensive RNA-Seq Gene Co-Expression Analysis Reveals Consistent Molecular Pathways in Hepatocellular Carcinoma across Diverse Risk Factors.

Talubo N, Tsai P, Tayo L Biology (Basel). 2024; 13(10).

PMID: 39452074 PMC: 11505157. DOI: 10.3390/biology13100765.


Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.

Li J, Yang B, Teng Z, Liu Y, Li D, Qu X Front Immunol. 2024; 15:1430196.

PMID: 39355238 PMC: 11442238. DOI: 10.3389/fimmu.2024.1430196.


Single-nucleus and spatial transcriptome reveal adrenal homeostasis in normal and tumoural adrenal glands.

Altieri B, Secener A, Sai S, Fischer C, Sbiera S, Arampatzi P Clin Transl Med. 2024; 14(8):e1798.

PMID: 39167619 PMC: 11338279. DOI: 10.1002/ctm2.1798.